Skip to main content

Production of Inhibin-Related Peptides by Ovarian Tumors

  • Chapter
  • 83 Accesses

Part of the Serono Symposia USA book series (SERONOSYMP)

Abstract

Ovarian cancer is the most common fatal gynecological malignancy, responsible for more deaths than all other forms of gynecological cancer combined. Lifetime risks for development of the disease are estimated to lie in the range of 1 in 80 to 1 in 100, with a population prevalence of approximately 30 per 100,000 women. Most patients with the disease present at an advanced stage, with 30% surviving for 5 years with a diagnosis of stage 3 epithelial malignancy (representing local and pelvic extraperitoneal spread) while only 5%–10% survive with stage 4 disease (disseminated malignancy).

Keywords

  • Ovarian Cancer
  • Granulosa Cell
  • Ovarian Tumor
  • Mucinous Tumor
  • Granulosa Cell Tumor

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-1-4612-1874-6_15
  • Chapter length: 8 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   79.99
Price excludes VAT (USA)
  • ISBN: 978-1-4612-1874-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   99.99
Price excludes VAT (USA)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Burger HG, Fuller PJ. The inhibin/activin family and ovarian cancer. Trends Endocrinol Metab 1996;7:197–202.

    PubMed  CrossRef  CAS  Google Scholar 

  2. Lappöhn RE, Burger HG, Bouma J, Bangah M, Krans M, de Bruijn H. Inhibin as a marker for granulosa-cell tumors. N Engl J Med 1989;321:790–3.

    PubMed  CrossRef  Google Scholar 

  3. Kauppila A, Bangah M, Burger HG, Martikainen H. GnRH agonist therapy in advanced/recurrent granulosa cell tumors: further evidence of a role of inhibin monitoring response to treament. Gynecol Endocrinol 1992;6:271–4.

    PubMed  CrossRef  CAS  Google Scholar 

  4. Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, et al. Inhibin: a serum marker for mucinous ovarian cancers. N Engl J Med 1993;329:1539–42.

    PubMed  CrossRef  CAS  Google Scholar 

  5. Burger HG. Clincial review—Clinical utility of inhibin measurements. J Clin Endocrinol Metab 1993;76:1391–6.

    PubMed  CrossRef  CAS  Google Scholar 

  6. Jobling T, Mamers P, Healy DL, MacLachlan V, Burger HG, Quinn M, et al. A prospective study of inhibin in granulosa cell tumors of the ovary. Gynecol Oncol 1994;55:285–9.

    PubMed  CrossRef  CAS  Google Scholar 

  7. Groome NP, Illingworth PG, O’Brien M, Cooke I, Ganesan TS, Baird DT, et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol 1994;40:717–23.

    CrossRef  CAS  Google Scholar 

  8. Groome NP, Illingworth PJ, O’Brien M, Roger PAL, Rodger FE, Mather JP, et al. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401–5.

    PubMed  CrossRef  CAS  Google Scholar 

  9. Burger HG, Robertson DM, Cahir N, Mamers P, Healy DL, Jobling T, et al. Characterisation of inhibin immunoreactivity in post-menopausal women with ovarian tumours. Clin Endocrinol 1996;44:413–8.

    CrossRef  CAS  Google Scholar 

  10. Cooke I, O’Brien M, Charnock FM, Groome NP, Ganesan TS. Inhibin as a marker for ovarian cancer. Br J Cancer 1995;71:1046–50.

    PubMed  CrossRef  CAS  Google Scholar 

  11. Robertson DM, Burger HG, Sullivan J, Cahir N, Groome N, Poncelet E, et al. Biological and immunological characterisation of inhibin forms in human plasma. J Clin Endocrinol Metab 1996;81:669–76.

    PubMed  CrossRef  CAS  Google Scholar 

  12. Sluijmer AV, Heineman MJ, Evers JLH, de Jong FH. Peripheral vein, ovarian vein and ovarian tissue levels of inhibin in a postmenopausal patient with a granulosa cell tumour. Acta Endocrinol (Copenh) 1993;129:311–14.

    CAS  Google Scholar 

  13. Gurusinghe CJ, Healy DL, Jobling T, Mamers P, Burger HG. Inhibin and activin are demonstrable by immunohistochemisty in ovarian tumor tissue. Gynecol Oncol 1995;57:27–32.

    PubMed  CrossRef  CAS  Google Scholar 

  14. Matzuk MM, Finegold MK, Su JG, Hsueh AJ, Bradley A. Alpha-inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature (Lond) 1992;360:313–9.

    CrossRef  CAS  Google Scholar 

  15. Coerver KA, Woodruff TK, Finegold MJ, Mather J, Bradley A, Matzuk MM. Activin signalling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient, mice. Mol Endocrinol 1996;10:534–43.

    PubMed  CrossRef  CAS  Google Scholar 

  16. Shen Y, Mamers P, Jobling T, Burger HG, Fuller PJ. Absence of the previously reported G-protein oncogence (gip21in ovarian granulosa cell tumors. J Clin Endocrinol Metab 1996;81:4159–61.

    PubMed  CrossRef  CAS  Google Scholar 

  17. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H. Two G protein oncogenes in human endocrine tumors. Science 1990;249:655–9.

    PubMed  CrossRef  CAS  Google Scholar 

Download references

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 1997 Springer Science+Business Media New York

About this chapter

Cite this chapter

Burger, H.G. et al. (1997). Production of Inhibin-Related Peptides by Ovarian Tumors. In: Aono, T., Sugino, H., Vale, W.W. (eds) Inhibin, Activin and Follistatin. Serono Symposia USA. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-1874-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-1874-6_15

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-7320-2

  • Online ISBN: 978-1-4612-1874-6

  • eBook Packages: Springer Book Archive